



UNIVERSITI PUTRA MALAYSIA

**EFFLUX INHIBITORY ACTIVITY OF SELECTED PHYTO-COMPOUNDS
AGAINST CLINICAL ISOLATES OF MULTIDRUG-RESISTANT
*STAPHYLOCOCCUS AUREUS***

SAIFUL AZMI BIN JOHARI

FBSB 2007 8

**EFFLUX INHIBITORY ACTIVITY OF SELECTED PHYTO-COMPOUNDS
AGAINST CLINICAL ISOLATES OF MULTIDRUG-RESISTANT
*STAPHYLOCOCCUS AUREUS***

By

SAIFUL AZMI BIN JOHARI

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
fulfilment of the Requirements for the Degree of Master of Science**

June 2007



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

**EFFLUX INHIBITORY ACTIVITY OF SELECTED PHYTO-COMPOUNDS
AGAINST CLINICAL ISOLATES OF MULTIDRUG-RESISTANT
*STAPHYLOCOCCUS AUREUS***

By

SAIFUL AZMI BIN JOHARI

June 2007

Chairman: Professor Abdul Manaf Ali, PhD

Faculty: Biotechnology and Biomolecular Sciences

Multidrug-resistant *Staphylococcus aureus* (MRSA) has been reported as one of the main cause of nosocomial infection in the world and ranks as one of the most difficult bacteria to treat in hospitalized patients. Apparently, these multidrug resistance (MDR) traits are caused by an array of MDR efflux pumps in *S. aureus*. In this study, a panel of identified clinical *S. aureus* isolates were tested for their multidrug-resistance profile, detection of efflux genes and evaluated against selected phyto-compounds. From the 26 bacterial isolates acquired from two teaching hospitals (HUKM and UMMC) and three ATCC *S. aureus* reference strains, 19 were confirmed as *S. aureus* isolates. Out of the 19 isolates, 14 were confirmed as methicillin-resistant *S. aureus* (MetRSA) via phenotypic and genotypic methods. Fourteen MetRSA isolates exhibit multidrug-resistance against amikacin, erythromycin, gentamicin, norfloxacin, tetracycline and trimethoprim. A methicillin-sensitive *S. aureus* (MetSSA) with multidrug-resistant trait was also detected. Apart from vancomycin, mupirocin seems to be the most effective antibiotic against all *S. aureus* isolates. Two MDR efflux genes (*mdeA* and *norA*) were detected in all isolates tested. Out of the 19 isolates, 18 harboured the *mdeA* gene while 16 isolates



contained the *norA* gene. Active efflux activity in *S. aureus* was detected using modified minimum inhibitory concentration (MIC) assay with ethidium bromide and reserpine as the efflux substrate and efflux inhibitor respectively. From this assay, two MRSA clinical isolates and one ATCC 25923 *S. aureus* reference strain were selected as test strains against 37 selected phyto-compounds consisting of alkaloids, flavonoids, coumarins and essential oils. Nine compounds namely quinine, harmaline, piperine, cinnamon oil, dicumarol, eriodictyol-7,4'-dimethyl ether, 2',4-dihydroxy-4',5',6'-trimethoxychalcone and naringenin-4'-methyl ether exhibited good efflux inhibitory activity as compared to reserpine. The first two are alkaloids with a methoxyl group at position C6 of an indole and quinolone skeleton, respectively. The last three are flavonoids from different sub-classes of flavanone (eriodictyol-7,4'-dimethyl and ether naringenin-4'-methyl ether) and chalcone (2',4-dihydroxy-4',5',6'-trimethoxychalcone). The similarity observed amongst member of the latter group is the presence of two hydroxyl group attached to their skeletal structures.



Abstrak thesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**AKTIVITI PERENCATAN EFLUKS DARI KOMPOUN-FITO TERPILIH
TERHADAP PENCILAN KLINIKAL *STAPHYLOCOCCUS AUREUS*
RINTANG-PELBAGAI-DADAH**

Oleh

SAIFUL AZMI BIN JOHARI

Jun 2007

Pengerusi: Profesor Abdul Manaf Ali, PhD

Fakulti: Bioteknologi dan Sains Biomolekul

Staphylococcus aureus rintang-pelbagai-dadah (MRSA) telah dilaporkan menjadi punca utama jangkitan nosokomial di dunia dan tersenarai sebagai salah satu bakteria yang paling susah untuk di rawat pada pesakit hospital. Sifat rintang-pelbagai-dadah (MDR) ini adalah disebabkan oleh sekumpulan pam efluks pada *S. aureus*. Di dalam kajian ini, satu panel pencilan klinikal *S. aureus* yang telah dikenalpasti sebagai rintang-pelbagai-dadah dengan gen-gen efluks telah digunakan untuk menilai potensi perencatan efluks pada sebatian-fito terpilih. Daripada 26 pencilan bakteria yang diperoleh dari dua hospital pembelajaran (HUKM dan UMMC), 19 telah dipastikan sebagai pencilan *S. aureus*. Daripada 19 pencilan tersebut, 14 merupakan *S. aureus* rintang-methicilin (MetRSA) melalui ujian-ujian fenotipik dan genotipik. Empat belas pencilan MetRSA menunjukkan ciri rintang-pelbagai-dadah terhadap amikacin, erythromycin, gentamycin, norfloxacin, tetracycline dan trimethoprim. Satu *S. aureus* rintang-methicilin (MetSSA) dengan ciri rintang-pelbagai-dadah juga dikesan. Selain daripada vancomycin, mupirocin didapati yang paling efektif terhadap semua pencilan *S. aureus*. Dua gen efluks MDR (*mdeA* dan *norA*) di kesan daripada pencilan *S. aureus* yang ada. Lapan



belas pencilan menunjukkan kehadiran gen *mdeA* manakala 16 pencilan mengandungi gen *norA*. Aktiviti efluks yang aktif di kesan menggunakan kaedah kepekatan perencatan minimum (MIC) yang telah diubahsuai dengan ethidium bromide sebagai substrat efluks dan reserpine sebagai perencat efluks. Dari kaedah tersebut, dua pencilan klinikal MRSA dan satu strain rujukan *S. aureus* ATCC 25923 telah di pilih sebagai pencilan ujian terhadap 37 komponen-fito terdiri dari kumpulan-kumpulan komponen tumbuhan yang berbeza iaitu alkaloids, flavonoids, coumarins dan minyak pati. Sembilan sebatian iaitu quinine, harmaline, piperine, cinnamon oil, dicumarol, eriodictyol-7,4'-dimethyl ether, 2',4-dihydroxy-4',5',6'-trimethoxychalcone dan naringenin-4'-methyl ether menunjukkan aktiviti perencatan efluks yang baik berbanding reserpine. Dua sebatian pertama adalah sebatian alkaloid dengan kumpulan metoksil pada posisi C6 di struktur asas indole dan quinolone. Tiga sebatian terakhir merupakan sebatian flavonoid dari sub-kelas flavanone (eriodictyol-7,4'-dimethyl dan ether naringenin-4'-methyl ether) dan chalcone (2',4-dihydroxy-4',5',6'-trimethoxychalcone). Persamaan yang dapat diperhatikan adalah kehadiran dua kumpulan hidroksil pada struktur asas sebatian-sebatian tersebut.



ACKNOWLEDGEMENTS

In the name of God, Most gracious, Most Merciful, Alhamdulillah, with Allah's permission I have completed the preparation of the manuscript, which His help enables me to develop and prepare myself with knowledge of science and technology which is essential for the betterment of humankind.

My deepest gratitude and respect to my kind project advisor, Prof. Dr. Abd. Manaf Ali, Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences (FBSB), Universiti Putra Malaysia (UPM) and as the chairman of the supervisory committee for his continuous invaluable advice, constructive suggestions and guidance to complete this interesting research project.

I would like to extend my appreciation to my supervisory committee; Dr. Shuhaimi Mustafa, Department of Microbiology, FBSB, UPM and Mdm Mastura Mohtar (the one responsible for the original idea of this research), Antimicrobial Laboratory, Medicinal Plants Programme, Biotechnology Division, Forest Research Institute of Malaysia (FRIM), for their critical and technical discussions and their kindness to allow me to use their laboratory facilities. My sincere thank also extended to FRIM and the Ministry of Science, Technology and Innovations (MOSTI), the Government of Malaysia for the financial support provided through the Young Scientist Grant, Research Fellowship Scheme and the Intensified Research in Priority Areas (IRPA) for this research.



My grateful acknowledge is due to my colleagues; Mr. Azli Ismail (IMR) and Mr. Zarizal Suhaili (UPM) for their technical support and discussions on the molecular aspect of the study; Dr. Ling Sui Kiong from the Phytochemistry Unit, Medicinal Plants Programme, FRIM for lending me her precious time to help me in the flavonoids analysis and the limited supply of the precious flavonoid compounds isolated from *C. odorata*; Mr. Abd. Rashid Li also from the Chemistry Unit, FRIM for assisting me in the alkaloid structure discussions; my co-workers in FRIM, Mdm Mazurah Mohd Isa and Mdm Hannan Abd Wahab for their help in preparation of the microbiology component of my research and to all my friends in Lab 202 (Hanim, Anas, Atun, Faizah and Huda) and Tissue Culture Lab (Intan, As, Hana, Fahmi, Aeyd, Illa) for their cooperation during my study here. To my beloved mother, Safiah Yusof and my family (Ang, Nizam, Cik Dah, uncles and cousins), for their understanding and constant support throughout my study. To my newly wedded wife, Norhayati Ahamd, thank you for your love and patience with me in preparing the final drafts of the thesis.

Last, but not least, I would like to express my thanks and gratitude to Prof. Dr. Nordiah Awang Jalil from Hospital Universiti Kebangsaan Malaysia (HUKM) and Dr. Chua Kek Heng from University Malaya Medical Center (UMMC) for their contribution of *S. aureus* clinical isolates for this research and to all of my friends, administrative staffs and students in FRIM, UPM and UM Medical Library for their direct or indirect involvement in completing this study.



I certify that an Examination Committee has met on _____ to conduct the final examination of Saiful Azmi Johari on his Master of Science thesis entitled “Efflux inhibitory Profile of Selected Phyto-compounds against Clinical Isolates of Multidrug-resistant *Staphylococcus aureus* (MRSA)” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

Chairman, PhD

Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Chairman)

Internal Examiner 1, PhD

Faculty of Food Science and Technology
Universiti Putra Malaysia
(Internal Examiner)

Internal Examiner 2, PhD

Faculty of Food Science and Technology
Universiti Putra Malaysia
(Internal Examiner)

External Examiner, PhD

School of Biological Sciences
Universiti Sains Malaysia
(External Examiner)

HASANAH MOHD GHAZALI, PhD

Professor/Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:



This thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Abd. Manaf Ali, PhD

Professor

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Chairman)

Shuhaimi Mustafa, PhD

Associate Professor

Faculty of Biotechnology and Biomolecular Sciences

Universiti Putra Malaysia

(Member)

Mastura Mohtar, M.Sc.

Senior Research Officer

Biotechnology Division

Forest Research Institute of Malaysia

(Member)

AINI IDERIS, PhD

Professor and Dean

School of Graduate Studies

Universiti Putra Malaysia

Date: 13 September 2007



DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.

SAIFUL AZMI JOHARI

Date: 19 July 2007



TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	iv
ACKNOWLEDGEMENTS	vi
APPROVAL	viii
DECLARATION	x
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xvii
CHAPTER	
I INTRODUCTION	19
II LITERATURE REVIEW	
Antibiotics Resistance in Bacteria	24
Introduction	24
Target Site Mutation	25
Membrane Impermeability	27
Enzymatic Modification or Destruction	29
Efflux Pumps	30
Emergence of Methicillin-resistant <i>S. aureus</i> (MetRSA) and Multidrug-resistant <i>S. aureus</i> (MRSA)	32
Anti-Staphylococcal Activity from Plant Compound/Extracts	37
The Search for MRSA Efflux Pump Inhibitors	40
III IDENTIFICATION, DETECTION AND ANTIBIOTIC SUSCEPTIBILITY PROFILE OF <i>S. AUREUS</i> AND MetRSA CLINICAL ISOLATES	
Introduction	46
Materials and Methods	49
Microbial Maintenance and Media Used	49
Gram Differentiation	49
<i>S. aureus</i> Identification and Detection	50
MetRSA Phenotypic Detection	51
<i>S. aureus</i> /MetRSA Genotypic Detection	51
Antibiotic Susceptibility Test (Disc Diffusion)	52
Antibiotic Susceptibility Test (E-Test)	53
Results	53
Gram Differentiation	53
<i>S. aureus</i> Identification and Detection	55
MetRSA Phenotypic Detection	55
<i>S. aureus</i> /MetRSA Genotypic Detection	57
Disc Diffusion Test	57



	E-Test	62
	Discussion	62
IV	DETECTION AND ANALYSIS OF EFFLUX GENES IN <i>S. AUREUS</i> AND MetRSA CLINICAL ISOLATES	
	Introduction	72
	Materials and Methods	73
	Genomic DNA Extraction	73
	<i>In silico</i> and Actual PCR Amplification Procedures	74
	DNA Sequence Determination	74
	Results	75
	<i>In silico</i> PCR Amplification of <i>norA</i> and <i>mdeA</i> Genes	75
	Actual PCR Amplification of <i>norA</i> and <i>mdeA</i> Genes	77
	DNA Sequencing Results	77
	Discussion	83
V	OPTIMIZATION OF ACTIVE EFFLUX DETECTION USING MINIMUM INHIBITORY CONCENTRATION (MIC) ASSAY	
	Introduction	88
	Materials and Methods	89
	Compounds and Chemical Used	89
	Minimum Inhibition Concentration (MIC) Value	89
	Determination Assay	
	Modified MIC Assay (Efflux Assay)	90
	Results	91
	Discussion	93
VI	EVALUATION OF POTENTIAL EFFLUX PUMP INHIBITORS FROM SELECTED PHYTO-COMPOUNDS USING MIC-EFFLUX ASSAY	
	Introduction	98
	Materials and Methods	100
	Bacterial Isolates Used	100
	Compounds and Chemicals Used	101
	Minimum Inhibition Concentration (MIC) Value	101
	Determination Assay	
	Modified MIC Assay (Efflux Assay)	102
	Results	103
	MIC Value Determination Assay	103
	Efflux Assay using 15 Standard Alkaloids	103
	Efflux Assay using Flavonoids isolated from <i>C. odorata</i> and Additional Standard Flavonoids	107
	Efflux Assay using Coumarins and Essential Oils	107
	Discussion	110
VII	GENERAL CONCLUSION	124



BIBLIOGRAPHY	125
APPENDICES	159
BIODATA OF THE AUTHOR	203
LIST OF PUBLICATIONS	204



LIST OF TABLES

Table		Page
1	Results of the Gram differentiation, isolation and detection of <i>S. aureus</i> using phenotypic methods.	54
2	Results of the MetRSA detection using phenotypic methods.	56
3	Antibiogram profile of <i>S. aureus</i> clinical isolates and ATCC strains against selected antibiotics.	60
4	Vancomycin susceptibility against <i>S. aureus</i> clinical isolates and ATCC strains using E-test strips.	63
5	<i>In silico</i> PCR results using the primers for <i>norA</i> and <i>mdeA</i> detection.	76
6	Summary of the <i>in silico</i> nucleotide sequence alignment analysis for MSSA476 (<i>norA</i>) and MRSA252 (<i>mdeA</i>) against all available <i>S. aureus</i> database in NCBI using the BLASTN programme.	78
7	Summary of the nucleotide sequence alignment analysis for <i>norA</i> using N441 and U949 against all available <i>S. aureus</i> database in NCBI using the BLASTN programme.	82
8	Summary of the nucleotide sequence alignment analysis for <i>mdeA</i> using N829 and UM2 against all available <i>S. aureus</i> database in NCBI using the BLASTN programme.	84
9	Minimum inhibitory concentration (MIC) value determination of the efflux substrates /inhibitors and its combinations against MRSA/ <i>S. aureus</i> isolates used in this study.	92
10	MIC of all the 37 compounds used in this study.	104
11	MIC of the efflux substrate, EtBr alone and in combination with the 15 standard alkaloids.	106
12	MIC of the efflux substrate, EtBr alone and in combination with the 10 flavonoids isolated from <i>Chromolaena odorata</i> .	108
13	MIC of the efflux substrate, EtBr alone and in combination with the 12 compounds.	109



LIST OF FIGURES

Figure		Page
1	Distribution of antibiotic resistance in three Malaysian Hospital	36
2	A model of synergistic action of berberine and an efflux inhibitor that are both produced by <i>B. fremontii</i> .	43
3a	PCR product of the <i>nuc</i> gene (278 bp) from the HUKM isolates and ATCC Standard strains.	58
3b	PCR product of the <i>nuc</i> gene (278 bp) from the UMMC isolates.	58
4a	PCR product of the <i>mecA</i> gene (533 bp) from the HUKM isolates and the ATCC standard strains.	59
4b	PCR product of the <i>mecA</i> gene from the UMMC isolates.	59
5	<i>In silico</i> nucleotide sequence alignment analysis for <i>norA</i> using MSSA476 with BLASTN programme.	160
6	<i>In silico</i> nucleotide sequence alignment analysis for <i>mdeA</i> using MRSA252 with BLASTN programme.	172
7	PCR product of the <i>norA</i> gene (726 bp) from the HUKM isolates and ATCC standard strains.	79
8	PCR product of the <i>mdeA</i> gene (156 bp) from the HUKM isolates and the ATCC standard strains.	80
9	Nucleotide sequence alignment analysis for <i>norA</i> from N441 using BLASTN programme.	175
10	Nucleotide sequence alignment analysis for <i>norA</i> from U949 using BLASTN programme.	186
11	Nucleotide sequence alignment analysis for <i>mdeA</i> from N829 using BLASTN programme.	197
12	Nucleotide sequence alignment analysis for <i>mdeA</i> from UM2 using BLASTN programme.	199
13	DNA Sequencing Result for <i>norA</i> from N441.	202
14	DNA Sequencing Result for <i>norA</i> from U949.	202



15	DNA Sequencing Result for <i>mdeA</i> from N829.	202
16	DNA Sequencing Result for <i>mdeA</i> from UM2.	202
17	Different classes and numbering system of the alkaloids and flavonoids used in this study.	105
18	Molecular structures of the standard alkaloids used in this study.	113
19	Molecular structures of the flavonoids isolated from <i>Chromolena odorata</i> used in this study.	116
20	Molecular structures of the other compounds used in this study.	118



LIST OF ABBREVIATIONS

β	beta
CDC	Centers for Disease Control and Prevention
MetRSA	methicillin-resistant <i>Staphylococcus aureus</i>
MRSA	multidrug-resistant <i>Staphylococcus aureus</i>
MetSSA	methicillin-susceptible <i>Staphylococcus aureus</i>
VRSA	vancomycin-resistant <i>Staphylococcus aureus</i>
%	percentage
>	more than
<	less than
\geq	more than or equal to
\leq	less than or equal to
PBP2a	Penicillin binding protein 2a
ATP	Adenosine triphosphate
MDR	multidrug resistant
UMMC	University Malaya Medical Center
HUKM	Hospital Universiti Kebangsaan Malaysia
sp	species
CCCP	carbonyl cyanide 3-chlorophenylhydrazone
h	hour
min	Minutes
NCCLS	National Committee on Clinical Laboratory Standards



BSAC	British Society for Antimicrobial Chemotherapy
PCR	polymerase chain reaction
TSB	Trypticase soy broth
TSA	Trypticase soy agar
MHA	Mueller-Hinton agar
MHB	Mueller-Hinton broth
VJA	Vogel-Johnson agar
ATCC	American Type Culture Collection
°C	degree celcius
µl	microliter
µg	microgram
X g	times gravity
bp	base pair
V	volt
DNA	deoxyribonucleic acid
NaCl	sodium chloride
MIC	minimum inhibitory concentration
PMF	proton motif force
BLASTN	Nucleotide-nucleotide Basic Local Alignment Search Tool
EtBr	ethidium bromide
µM	micromolar
H ⁺	proton



Table 1: Results of the Gram differentiation, isolation and detection of *S. aureus* using phenotypic methods. Gram positive bacteria will have no colour change (transparent) and watery suspension in the L-alanine peptidase and 3% KOH tests, respectively. Only *S. aureus* isolates would produce black colonies with yellow ring growth and agglutinates in the Vogel-Johnson agar and the Pastorex Staph-Plus Test respectively.

Isolates	Gram differentiation		Vogel-Johnson Agar	Pastorex Staph-Plus Test
	L-alanine peptidase test	3% KOH		
N 391	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
N 441	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
N 829	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
N 850	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
N 1406	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
U 949	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 1	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 2	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 3	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 6	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 7	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 9	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 10	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 11	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 13	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
UM 14	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
ATCC 25923 <i>S. aureus</i>	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
ATCC 29213 <i>S. aureus</i>	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
ATCC 33591 MetRSA	No color change	Watery suspension	Black colonies with yellow ring growth	Agglutination
ATCC 35218 <i>E. coli</i>	Yellow coloration	Sticky suspension	N/A	No agglutination
ATCC 700728 <i>E. coli</i>	Yellow coloration	Sticky suspension	N/A	No agglutination

Note: N/A = Not Applicable



Table 3: Antibiogram profile of *S. aureus* clinical isolates and ATCC strains against selected antibiotics. Disc diffusion breakpoints are based on the NCCLS guidelines except for * which are based on the BSAC guidelines.

ISOLATES	Antibiotics used / Diameter of inhibition zone (mm)															
	AK	AMP	C	DA	E	FD*	CN	MUP*	NOR	OX	RD	S	TEC	TE	W	V
N 391	R	R	S	R	R	R	R	S	R	R	S	R	S	R	R	S
N 441	R	R	S	S	R	S	R	S	I	R	R	R	S	R	R	S
N 829; U 949	R	R	S	S	R	S	R	S	R	R	S	R	S	R	R	S
N 850	R	R	S	S	R	R	R	S	R	R	R	R	S	R	R	S
N 1406	R	R	S	S	R	R	R	S	R	R	S	R	S	R	R	S
UM 1	R	R	R	S	R	I	R	S	R	R	S	R	S	R	R	S
UM 2; UM 9	R	R	R	S	R	S	R	S	R	R	S	R	S	R	R	S
UM 3	R	R	S	S	S	S	R	S	R	R	R	ND	S	R	R	S
UM 6	S	S	S	S	S	R	S	S	S	S	S	ND	S	S	S	S
UM 7	S	S	S	S	S	S	S	S	S	S	S	ND	S	S	S	S
UM 10	R	R	R	R	R	S	R	S	R	R	S	R	S	R	R	S
UM 11	S	R	S	S	S	R	S	S	R	S	S	ND	I	I	S	S
UM 13	R	R	S	S	R	R	R	S	R	R	R	R	I	R	R	S
UM 14	R	R	R	R	R	R	R	S	R	R	S	R	S	R	R	S
ATCC 25923	S	S	S	S	I	R	S	S	S	S	S	ND	S	S	S	S
ATCC 29213	S	S	S	S	I	R	S	I	S	S	S	ND	I	S	S	S
ATCC 33591	S	R	R	R	R	R	S	S	S	R	S	R	S	R	S	S

Degree of susceptibility: R = resistant; I = intermediate; S = susceptible; ND = Not determined

Antibiotics used in this study : AK = amikacin, 30 µg; AMP = ampicillin, 10 µg; C = chloramphenicol, 30 µg; DA = clindamycin, 2 µg; E = erythromycin, 15 µg; FD = fusidic acid, 10 µg; CN = gentamicin, 10 µg; MUP = mupirocin, 5 µg; NOR = norfloxacin, 10 µg; OX = oxacillin, 1 µg; RD = rifampicin, 5 µg; S = Streptomycin, 10 µg; TEC = teicoplanin, 30 µg; TE = tetracycline, 30 µg; W = trimethoprim, 5 µg; V = vancomycin, 30 µg.



Table 5: *In silico* PCR results using the primers for *norA* and *mdeA* detection.

Target Genes	<i>norA</i>		<i>mdeA</i>	
Staphylococci Strains	No. of nucleotides mismatched allowed	Amplification Results	No. of nucleotides mismatched allowed	Amplification Results
<i>S. aureus</i> RF122	0	+	0	+
<i>S. aureus</i> strain Mu50	0	+	0	+
<i>S. aureus</i> subsp. <i>aureus</i> COL	0	+	0	+
<i>S. aureus</i> subsp. <i>aureus</i> MRSA252	2	-	0	+
<i>S. aureus</i> subsp. <i>aureus</i> MSSA476	0	+	0	+
<i>S. aureus</i> subsp. <i>aureus</i> MW2	0	+	0	+
<i>S. aureus</i> subsp. <i>aureus</i> N315	0	+	0	+
<i>S. aureus</i> subsp. <i>aureus</i> NCTC 8325	0	+	0	+
<i>S. aureus</i> subsp. <i>aureus</i> USA300	0	+	0	+
<i>S. epidermidis</i> ATCC 12228*	2	-	2	-

* *S. epidermidis* ATCC 12228 was used a negative control isolate in the actual experiment.

Table 6: Summary of the *in silico* nucleotide sequence alignment analysis for MSSA476 (*norA*) and MRSA252 (*mdeA*) against all available *S. aureus* database in NCBI using the BLASTN programme.

No.	Ascension number	<i>S. aureus</i> strains/gene/plasmid	Nucleotide sequence alignment analysis (% of homology)	
			MSSA476 (<i>norA</i>)	MRSA252 (<i>mdeA</i>)
1	gi 47208328 dbj BA000017.4	Mu50	100	99
2	gi 49243355 emb BX571857.1	MSSA476	100	98
3	gi 47118312 dbj BA000033.2	MW2	100	98
4	gi 47118324 dbj BA000018.3	N315	100	99
5	gi 216974 dbj D90119.1 STANORA	N/A	100	ND
6	gi 57284222 gb CP000046.1	COL	99	98
7	gi 87201381 gb CP000253.1	NCTC8325	99	98
8	gi 87125858 gb CP000255.1	USA300	99	98
9	gi 693734 gb S74031.1	ISP794	99	ND
10	gi 82655308 emb AJ938182.1	RF122	99	99
11	gi 152647 gb M62960.1 SA2NORA	pSA209	99	ND
12	gi 21328207 dbj AB086042.1	N/A	100	ND
13	gi 4115706 dbj AB019536.1	norA23	94.5	ND
14	gi 49240382 emb BX571856.1	MRSA252	94	100
15	gi 153054 gb M97169.1 STANORAX	N/A	93	ND
16	gi 295163 gb M80252.1 STANORA11	norA1199	93	ND
17	gi 19745057 gb AC090968.14	NCTC8325 (<i>sabac</i> -126)	ND	98
18	gi 27316888 gb AE015929.1*	ATCC12228*	84.7	100 (only 20 nucleotides)

N/A = Not Available

ND = Not Detected

* *S. epidermidis* (control strain)



Table 7: Summary of the nucleotide sequence alignment analysis for *norA* using N441 and U949 against all available *S. aureus* database in NCBI using the BLASTN programme.

No.	Ascension number	<i>S. aureus</i> strains/gene/plasmid	Nucleotide sequence alignment analysis for <i>norA</i> (% of homology)	
			N441	U949
1	gi 57284222 gb CP000046.1	COL	100	100
2	gi 87201381 gb CP000253.1	NCTC8325	100	100
3	gi 87125858 gb CP000255.1	USA300	100	100
4	gi 693734 gb S74031.1	ISP794	100	100
5	gi 47208328 dbj BA000017.4	Mu50	99	99
6	gi 49243355 emb BX571857.1	MSSA476	99	99
7	gi 47118312 dbj BA000033.2	MW2	99	99
8	gi 47118324 dbj BA000018.3	N315	99	99
9	gi 216974 dbj D90119.1 STANORA	N/A	99	99
10	gi 82655308 emb AJ938182.1	RF122	98	98
11	gi 152647 gb M62960.1 SA2NORA	pSA209	98	98
12	gi 21328207 dbj AB086042.1	N/A	99	99
13	gi 4115706 dbj AB019536.1	norA23	93.5	93.5
14	gi 49240382 emb BX571856.1	MRSA252	93.5	93.5
15	gi 153054 gb M97169.1 STANORAX	N/A	92.5	92.5
16	gi 295163 gb M80252.1 STANORA11	norA1199	92	92.5
17	gi 27316888 gb AE015929.1 *	ATCC12228*	81	81

N/A = Not Available

* *S. epidermidis* (control strain)



Table 8: Summary of the nucleotide sequence alignment analysis for *mdeA* using N829 and UM2 against all available *S. aureus* database in NCBI using the BLASTN programme.

No.	Ascension number	<i>S. aureus</i> strains/gene/plasmid	Nucleotide sequence alignment analysis for <i>mdeA</i> (% of homology)	
			N829	UM2
1	gi 47208328 dbj BA000017.4	Mu50	100	100
2	gi 57284222 gb CP000046.1	COL	100	100
3a	gi 87201381 gb CP000253.1	NCTC8325	100	100
3b	gi 19745057 gb AC090968.14	NCTC8325 (sabac-126)	100	100
4	gi 87125858 gb CP000255.1	USA300	100	100
5	gi 49243355 emb BX571857.1	MSSA476	100	100
6	gi 47118312 dbj BA000033.2	MW2	100	100
7	gi 47118324 dbj BA000018.3	N315	100	100
8	gi 82655308 emb AJ938182.1	RF122	100	100
9	gi 49240382 emb BX571856.1	MRSA252	99	99